In vitro, this model supported the concept that a subset of metastatic prostate cancers that have escaped AR dependence can rely on the FGF–FGFR–MAPK axis for survival, and that pathway inhibition suppresses growth of AR-indifferent tumors [123]. The gene discussed is AR; the disease is prostate carcinoma.